Amdocs Limited Reports First Quarter Fiscal 2025 Results
Amdocs (DOX) reported Q1 fiscal 2025 results with revenue of $1.11 billion, down 10.9% YoY as reported but up 1.7% YoY in pro forma constant currency. The company's managed services revenue reached $729 million, representing 66% of total revenue. GAAP diluted EPS was $1.33, while non-GAAP diluted EPS reached $1.66.
The company's twelve-month backlog increased to $4.14 billion, up $80 million sequentially and 2.7% YoY on a pro forma basis. During Q1, Amdocs repurchased $144 million of ordinary shares and maintained its fiscal 2025 outlook for revenue growth of 1%-4.5% YoY in pro forma constant currency. The company expects fiscal 2025 revenue to decline between 11.6% and 8.5% YoY as reported.
Profitability improved significantly in Q1, driven by the phase-out of low-margin activities and focus on operational excellence. The company reiterates its commitment to delivering double-digit total shareholder returns for the fifth consecutive year.
Amdocs (DOX) ha riportato i risultati del primo trimestre dell'anno fiscale 2025, con un fatturato di 1,11 miliardi di dollari, in calo del 10,9% anno su anno come riportato, ma in aumento dell'1,7% anno su anno in valuta costante pro forma. I ricavi delle servizi gestiti dell'azienda hanno raggiunto 729 milioni di dollari, rappresentando il 66% del fatturato totale. GAAP EPS diluito era di 1,33 dollari, mentre l'EPS diluito non GAAP ha raggiunto 1,66 dollari.
Il portafoglio ordini dell'azienda è aumentato a 4,14 miliardi di dollari, in crescita di 80 milioni di dollari rispetto al trimestre precedente e del 2,7% anno su anno su base pro forma. Durante il primo trimestre, Amdocs ha riacquistato azioni ordinarie per un valore di 144 milioni di dollari e ha mantenuto le previsioni per l'anno fiscale 2025 di una crescita del fatturato dell'1%-4,5% anno su anno in valuta costante pro forma. L'azienda prevede che il fatturato per l'anno fiscale 2025 scenderà tra l'11,6% e l'8,5% anno su anno come riportato.
La redditività è migliorata significativamente nel primo trimestre, grazie all'interruzione di attività a basso margine e al focus sull'eccellenza operativa. L'azienda ribadisce il suo impegno a garantire ritorni ai soci di capitale a due cifre per il quinto anno consecutivo.
Amdocs (DOX) reportó los resultados del primer trimestre del año fiscal 2025, con ingresos de $1.11 mil millones, una disminución del 10.9% interanual según lo reportado, pero un aumento del 1.7% interanual en moneda constante pro forma. Los ingresos de servicios gestionados de la compañía alcanzaron 729 millones de dólares, representando el 66% de los ingresos totales. GAAP EPS diluido fue de 1.33 dólares, mientras que el EPS diluido no GAAP alcanzó 1.66 dólares.
La cartera de pedidos de la empresa aumentó a $4.14 mil millones, con un incremento de 80 millones de dólares secuencialmente y un 2.7% interanual en una base pro forma. Durante el primer trimestre, Amdocs recompró 144 millones de dólares en acciones ordinarias y mantuvo su perspectiva para el año fiscal 2025 de un crecimiento de ingresos del 1%-4.5% interanual en moneda constante pro forma. Se espera que los ingresos del año fiscal 2025 disminuyan entre un 11.6% y un 8.5% interanual según lo reportado.
La rentabilidad mejoró significativamente en el primer trimestre, impulsada por la eliminación de actividades de bajo margen y el enfoque en la excelencia operativa. La empresa reitera su compromiso de ofrecer retornos totales a los accionistas de dos dígitos por quinto año consecutivo.
Amdocs (DOX)는 2025 회계 연도 1 분기 실적을 보고했습니다. 매출은 11억 1천만 달러로, 보고 기준으로 전년 대비 10.9% 감소했으나, 프로 포르마 상수 통화 기준으로는 전년 대비 1.7% 증가했습니다. 회사의 관리 서비스 매출은 7억 2900만 달러에 달해 전체 매출의 66%를 차지했습니다. GAAP 희석 주당순이익은 1.33달러였고, 비 GAAP 희석 주당순이익은 1.66달러에 도달했습니다.
회사의 12개월 백로그는 41억 4천만 달러로 증가했으며, 이는 직전 분기 대비 8천만 달러, 전년 대비로는 프로 포르마 기준으로 2.7% 증가한 수치입니다. 1분기 동안 Amdocs는 1억 4400만 달러의 보통주를 재매입했으며, 2025 회계 연도에 대한 매출 성장 전망인 1%~4.5%의 목표를 유지했습니다. 이 회사는 2025 회계 연도 매출이 보고 기준으로 전년 대비 11.6%에서 8.5% 감소할 것으로 예상합니다.
수익성은 저수익 활동의 단계적 중단과 운영 우수성에 대한 집중 덕분에 1분기에 크게 개선되었습니다. 회사는 다섯 번째 연속 최대 두 자릿수 주주 수익률 달성에 대한 의지를 재확인합니다.
Amdocs (DOX) a annoncé ses résultats pour le premier trimestre de l'exercice fiscal 2025, avec un chiffre d'affaires de 1,11 milliard de dollars, en baisse de 10,9 % d'une année sur l'autre selon les rapports, mais en hausse de 1,7 % d'une année sur l'autre en monnaie constante pro forma. Les revenus des services gérés de l'entreprise ont atteint 729 millions de dollars, représentant 66 % du chiffre d'affaires total. GAAP EPS dilué était de 1,33 dollar, tandis que l'EPS dilué non GAAP a atteint 1,66 dollar.
Le carnet de commandes de l'entreprise a augmenté à 4,14 milliards de dollars, une hausse de 80 millions de dollars par rapport au trimestre précédent et de 2,7 % d'une année sur l'autre sur une base pro forma. Au cours du premier trimestre, Amdocs a racheté pour 144 millions de dollars d'actions ordinaires et a maintenu ses prévisions pour l'exercice 2025 d'une croissance des revenus de 1 % à 4,5 % d'une année sur l'autre en monnaie constante pro forma. L'entreprise s'attend à ce que les revenus de l'exercice 2025 diminuent entre 11,6 % et 8,5 % d'une année sur l'autre selon les rapports.
La rentabilité s'est significativement améliorée au premier trimestre, portée par l'élimination des activités à faible marge et un accent sur l'excellence opérationnelle. L'entreprise réitère son engagement à fournir des rendements totaux à deux chiffres pour les actionnaires pour la cinquième année consécutive.
Amdocs (DOX) berichtete die Ergebnisse des ersten Quartals des Geschäftsjahres 2025 mit einem Umsatz von 1,11 Milliarden Dollar, was einem Rückgang von 10,9% im Jahresvergleich entspricht, jedoch einem Anstieg von 1,7% im Jahresvergleich in pro forma konstanter Währung. Die Umsätze aus Managed Services erreichten 729 Millionen Dollar und machen 66% des Gesamtumsatzes aus. GAAP verwässerter EPS betrug 1,33 Dollar, während der nicht-GAAP verwässerte EPS 1,66 Dollar erreichte.
Der Auftragsbestand des Unternehmens erhöhte sich auf 4,14 Milliarden Dollar, was einem Anstieg von 80 Millionen Dollar im Vergleich zum Vorquartal und 2,7% im Jahresvergleich auf pro forma Basis entspricht. Im ersten Quartal hat Amdocs Aktien im Wert von 144 Millionen Dollar zurückgekauft und seine Prognose für das Geschäftsjahr 2025 hinsichtlich des Umsatzwachstums von 1%-4,5% im Jahresvergleich in pro forma konstanter Währung beibehalten. Das Unternehmen erwartet, dass der Umsatz im Geschäftsjahr 2025 im Vergleich zum Vorjahr um 11,6% bis 8,5% zurückgehen wird.
Die Rentabilität hat sich im ersten Quartal erheblich verbessert, was auf das Auslaufen von Aktivitäten mit niedrigen Margen und den Fokus auf betriebliche Exzellenz zurückzuführen ist. Das Unternehmen bekräftigt sein Engagement, im fünften Jahr in Folge Zwei-Stelliges Gesamtrückfluss für die Aktionäre zu liefern.
- Non-GAAP operating margin improved by 310 basis points YoY to 21.2%
- Managed services revenue grew 0.9% YoY, representing 66% of total revenue
- Backlog increased by $80 million sequentially to $4.14 billion
- GAAP operating margin improved by 310 basis points YoY to 17.9%
- Free cash flow guidance maintained at $710-730 million for FY2025
- Revenue declined 10.9% YoY to $1.11 billion as reported
- Expects FY2025 revenue decline of 11.6%-8.5% YoY as reported
- Negative impact from foreign currency movements of $6 million vs guidance
Insights
The Q1 FY2025 results reveal Amdocs' successful execution of its strategic transformation, marked by deliberate revenue optimization and margin expansion. While the headline revenue decline of 10.9% to
The strategic exit from low-margin activities is proving highly accretive to profitability, evidenced by the 310 basis point improvement in GAAP operating margin to
The backlog growth of
The acquisition of Profinit for
Capital allocation remains balanced, with
Revenue of
Delivers Substantial Profitability Improvement, Reflecting Phase Out of Certain Non-Core, Low Margin Business Activities & Operational Efficiencies
12-Month Backlog of
Expects Fiscal 2025 Revenue Outlook of (11.6)%-(8.5)% YoY as Reported
Reiterates Fiscal 2025 Revenue Growth Outlook of
Reiterates Fiscal 2025 Target for Double-Digit Total Shareholder Returns(3)
First Quarter Fiscal 2025 Highlights
(All comparisons are against the prior year)
Revenue of
$1,110 million , down10.9% as reported due to the phase out of certain business activities, and up1.7% in pro forma(1) constant currency(2); revenue was slightly above the midpoint of the$1,095 -$1,135 million guidance range, adjusting for a negative impact from foreign currency movements of approximately$6 million compared to our guidance assumptionsManaged services revenue of
$729 million , equivalent to approximately66% of total revenue and up0.9% as compared to last year's first fiscal quarterGAAP diluted EPS of
$1.33 , above the guidance range of$1.20 -$1.29 Non-GAAP diluted EPS of
$1.66 , at the higher end of the guidance range of$1.61 -$1.67 GAAP operating income of
$199 million ; GAAP operating margin of17.9% , up 900 basis points as compared to the fourth fiscal quarter which included restructuring charges of$83 million , and up 310 basis points as compared to last year's first fiscal quarter, reflecting the phase out of certain non-core business activities and a continued focus on operational excellenceNon-GAAP operating income of
$235 million ; non-GAAP operating margin of21.2% , up 310 basis points as compared to last year's first fiscal quarter and up 250 basis points sequentially, reflecting the phase out of certain non-core business activities and a continued focus on operational excellenceFree cash flow of
$78 million , comprised of cash flow from operations of$106 million , less$27 million in net capital expenditures(4), including$23 million of restructuring payments; reiterates full year fiscal 2025 free cash outlook of$710 million to$730 million , excluding restructuring paymentsRepurchased
$144 million of ordinary shares during the first fiscal quarterTwelve-month backlog of
$4.14 billion , up approximately$80 million sequentially; adjusting for the phase out of certain business activities, twelve-month backlog was up2.7% (1) as compared to last year's first fiscal quarter
(1) For comparison purposes, pro forma adjusts first quarter fiscal year 2024 revenue by approximately
(2) Revenue on a constant currency basis assumes exchange rates in the current period were unchanged from the prior period
(3) Expected total shareholder return assumes midpoint of fiscal year 2025 non-GAAP EPS growth outlook, plus dividend yield
(4) Please refer to the Selected Financial Metrics tables below (figures may not sum because of rounding)
JERSEY CITY, NJ / ACCESS Newswire / February 4, 2025 / Amdocs Limited (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today reported operating results for the three months ended December 31, 2024.
"Fiscal 2025 is off to a solid start. First quarter revenue of
"Profitability rose significantly in Q1, driven by the previously announced phase-out of low-margin activities, and our focus on operational excellence, automation, and AI to drive ongoing efficiency gains. Further supporting our high level of business visibility, managed services accounted for roughly
Sheffer concluded, "As a market leader, we are proud of Amdocs' innovative, Gen AI-based solutions and our execution and mission critical operations expertise. We also have a pivotal role in supporting our customers growth, efficiency and industry consolidation strategies. Across our large addressable market, we see a rich and encouraging sales pipeline which we are working hard to monetize while navigating the continuously challenging demand environment. As to our fiscal 2025 outlook, we are reiterating our guidance for revenue growth of between
Revenue
(All comparisons are against the prior year period)
|
| In millions |
| |||
|
| Three months ended |
| |||
|
| December 31, 2024 |
| |||
| Actual |
|
| Guidance |
| |
|
|
|
|
|
|
|
Revenue |
|
|
|
| ||
Revenue Growth, as reported |
| (10.9)% |
|
|
|
|
Revenue Growth, pro-forma (1) constant currency (2) |
|
|
|
|
|
Revenue for the first fiscal quarter of 2025 was slightly above the midpoint of Amdocs' guidance, adjusting for negative impact from foreign currency movements of approximately
$6 million relative to our guidance assumptionsRevenue for the first fiscal quarter includes a negative impact from foreign currency movements of approximately
$4 million relative to the fourth quarter of fiscal 2024
Net Income and Earnings Per Share
|
| In thousands, except per share data |
| |||||
|
| Three months ended |
| |||||
|
| December 31, |
| |||||
| 2024 |
|
| 2023 |
| |||
GAAP Measures |
|
|
|
|
|
| ||
Net Income |
|
|
|
| ||||
Net Income attributable to Amdocs Limited |
|
|
|
| ||||
Diluted earnings per share |
|
|
|
| ||||
|
|
|
|
|
|
|
| |
Non-GAAP Measures |
|
|
|
|
|
|
|
|
Non-GAAP Net Income |
|
|
|
| ||||
Non-GAAP Net Income attributable to Amdocs Limited |
|
|
|
| ||||
Non-GAAP Diluted earnings per share |
|
|
|
|
Non-GAAP net income excludes amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition related liabilities measured at fair value, equity-based compensation expenses, restructuring charges, and other, net of related tax effects. For further details of the reconciliation of selected financial metrics from GAAP to Non-GAAP, please refer to the tables below.
Capital Allocation
M&A Activity: On December 31, 2024, Amdocs completed the acquisition of Profinit, a data science and engineering company, for a net consideration of approximately
$34 million with additional consideration to be paid later based on the achievement of certain performance objectives, as well as two smaller acquisitionsQuarterly Cash Dividend Program: On February 4, 2025, the Board approved the Company's next quarterly cash dividend payment at the new increased rate of
$0.52 7 per share, as approved at the January 2025 annual general meeting of shareholders and set March 31, 2025 as the record date for determining the shareholders entitled to receive the dividend, which will be payable on April 25, 2025Share Repurchase Activity: Repurchased
$144 million of ordinary shares during the first quarter of fiscal 2025
Twelve-month Backlog
Twelve-month backlog was
Second Quarter Fiscal 2025 Outlook
| In millions, except per share data |
| |
| Q2 - 2025 |
| |
Revenue |
|
| |
GAAP Diluted earnings per share |
|
| |
Non-GAAP Diluted earnings per share |
|
|
Second quarter revenue guidance assumes a negative
$3 million sequential impact from foreign currency fluctuations as compared to foreign currency rates prevailing at the end of the first quarter of fiscal 2025Second quarter non-GAAP diluted EPS guidance excludes primarily equity-based compensation expense of approximately
$0.20 -$0.22 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately$0.12 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effectsGAAP diluted EPS guidance does not include the impact of future restructuring charges
Full Year Fiscal 2025 Outlook
| FY 2025 - Year-over -Year growth |
| ||||||
| Current guidance |
|
| Previous guidance |
| |||
Revenue Growth, as reported |
| (11.6)%-(8.4)% |
|
| (10.9)%-(7.7)% |
| ||
Revenue Growth, Pro-forma (1) constant currency (2) |
|
|
|
| ||||
GAAP Diluted earnings per share |
|
|
|
| ||||
Non-GAAP Diluted earnings per share |
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
| FY 2025, in millions |
| |||||
|
| Current guidance |
|
| Previous guidance |
| ||
Free Cash Flow (4) |
|
|
|
|
Revenue growth on a pro forma(1), constant currency(2) basis adjusts fiscal 2024 revenue by approximately
$600 million to reflect the end of several low-margin, non-core business activities, including certain low-margin software and hardware partner activities, Vubiquity's transactional video on demand business and non-core subscription services; these activities substantially already ceased in the first quarter of fiscal 2025 and are not included in the full year fiscal 2025 revenue outlookFull year fiscal 2025 revenue guidance incorporates an expected negative impact from foreign currency fluctuations of approximately
0.6% year-over-year, as compared with a positive impact of approximately0.2% year-over-year previously, and includes some inorganic contributionNon-GAAP diluted earnings per share growth excludes primarily equity-based compensation expense of approximately
$0.84 -$0.90 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately$0.48 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effectsThe impact of the acquisitions on Amdocs' non-GAAP diluted earnings per share is expected to be immaterial in the full fiscal year 2025
GAAP diluted EPS guidance does not include the impact of future restructuring charges
Non-GAAP operating margin is anticipated to be within a range of
21.1% to21.7% for the full year fiscal 2025Non-GAAP operating margin is comprised of GAAP operating margin, excluding amortization on purchased intangible assets and other, equity-based compensation expense, restructuring charges, and changes in certain acquisitions related liabilities measured at fair value
Non-GAAP effective tax rate is anticipated to be within a range of
15% to17% for the full year fiscal 2025Free cash flow(4) is comprised of cash flow from operations, less net capital expenditures, and excludes payments related to restructuring charges
The forward-looking statements regarding our second fiscal quarter 2025 and full year fiscal 2025 guidance take into consideration the Company's current expectations regarding macro and industry specific risks and various uncertainties and certain assumptions that we will discuss on our earnings conference call. However, we note that market dynamics continue to shift rapidly and we cannot predict all possible outcomes, including those resulting from certain geopolitical events, the current inflationary environment, global or regional events, and the prevailing level of macro-economic, business and operational uncertainty, which have created, and continue to create, a significant amount of uncertainty, or from current and potential customer consolidation or their other strategic corporate activities.
Conference Call and Earnings Webcast Presentation Details
Amdocs will host a conference call and earnings webcast presentation on February 4, 2025 at 5:00 p.m. Eastern Time to discuss the Company's first quarter of fiscal 2025 results.
To participate in the call, please register here to receive the dial-in numbers and unique access PIN. The conference call and webcast will also be carried live on the Internet and may be accessed via the Amdocs website at https://investors.amdocs.com. Presentation slides will be available shortly before the webcast.
Non-GAAP Financial Measures
This release includes non-GAAP diluted earnings per share and other non-GAAP financial measures, including free cash flow, revenue on a constant currency(2) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth. These other non-GAAP measures exclude the following items:
amortization of purchased intangible assets and other acquisition-related costs;
changes in certain acquisition-related liabilities measured at fair value;
restructuring and unusual charges or benefits;
equity-based compensation expense;
other; and
tax effects related to the above.
Free cash flow equals cash generated by operating activities less net capital expenditures. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures.
Amdocs believes that the presentation of non-GAAP diluted earnings per share and other financial measures, including free cash flow(4), revenue on a constant currency(2) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business.
For its internal budgeting process and in monitoring the results of the business, Amdocs' management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition-related liabilities measured at fair value, restructuring and unusual charges or benefits, equity-based compensation expense, other and related tax effects. Amdocs' management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items.
Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, interest and other expenses, net, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below.
Supporting Resources
Keep up with Amdocs news by visiting the Company's website
Subscribe to Amdocs' RSS Feed and follow us on Twitter, Facebook, LinkedIn and YouTube
About Amdocs
Amdocs helps those who build the future to make it amazing. With our market-leading portfolio of software products and services, we unlock our customers' innovative potential, empowering them to provide next-generation communication and media experiences for both the individual end user and large enterprise customers. Our employees around the globe are here to accelerate service providers' migration to the cloud, enable them to differentiate in the 5G era, and digitalize and automate their operations. Listed on the NASDAQ Global Select Market, Amdocs had revenue of
For more information, visit Amdocs at www.amdocs.com.
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2024 filed on December 17, 2024.
Contact:
Matthew Smith
Head of Investor Relations
Amdocs
314-212-8328
E-mail: dox_info@amdocs.com
AMDOCS LIMITED
Consolidated Statements of Income
(In thousands, except per share data)
| Three months ended |
| ||||||
| 2024 |
|
| 2023 |
| |||
Revenue |
| $ | 1,110,055 |
|
| $ | 1,245,199 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
Cost of revenue |
|
| 682,259 |
|
|
| 812,744 |
|
Research and development |
|
| 84,333 |
|
|
| 89,207 |
|
Selling, general and administrative |
|
| 122,087 |
|
|
| 142,504 |
|
Amortization of purchased intangible assets and other |
|
| 15,759 |
|
|
| 16,410 |
|
Restructuring charges |
|
| 6,783 |
|
|
| - |
|
|
| 911,221 |
|
|
| 1,060,865 |
| |
Operating income |
|
| 198,834 |
|
|
| 184,334 |
|
Interest and other expense, net |
|
| (6,409 | ) |
|
| (9,778 | ) |
Income before income taxes |
|
| 192,425 |
|
|
| 174,556 |
|
Income tax expense |
|
| 40,573 |
|
|
| 25,834 |
|
Net income |
| $ | 151,852 |
|
| $ | 148,722 |
|
Net income attributable to noncontrolling interests |
|
| 719 |
|
|
| 757 |
|
Net income attributable to Amdocs Limited |
| $ | 151,133 |
|
| $ | 147,965 |
|
Basic earnings per share attributable to Amdocs Limited |
| $ | 1.34 |
|
| $ | 1.27 |
|
Diluted earnings per share attributable to Amdocs Limited |
| $ | 1.33 |
|
| $ | 1.26 |
|
Cash dividends declared per ordinary share |
| $ | 0.479 |
|
| $ | 0.435 |
|
Basic weighted average number of shares outstanding |
|
| 112,745 |
|
|
| 116,841 |
|
Diluted weighted average number of shares outstanding |
|
| 113,439 |
|
|
| 117,536 |
|
AMDOCS LIMITED
Selected Financial Metrics
(In thousands, except per share data)
| Three months ended |
| ||||||
| 2024 |
|
| 2023 |
| |||
|
|
|
|
|
|
| ||
Revenue |
| $ | 1,110,055 |
|
| $ | 1,245,199 |
|
Non-GAAP operating income |
|
| 235,398 |
|
|
| 225,241 |
|
Non-GAAP net income |
|
| 188,877 |
|
|
| 183,833 |
|
Non-GAAP net income attributable to Amdocs Limited |
|
| 188,158 |
|
|
| 183,076 |
|
Non-GAAP diluted earnings per share |
| $ | 1.66 |
|
| $ | 1.56 |
|
Diluted weighted average number of shares outstanding |
|
| 113,439 |
|
|
| 117,536 |
|
Free Cash Flows
(In thousands)
| Three months ended |
| ||||||
| 2024 |
|
| 2023 |
| |||
|
|
|
|
|
|
| ||
Net Cash Provided by Operating Activities |
| $ | 105,555 |
|
| $ | 182,387 |
|
Purchase of property and equipment, net (a) |
|
| (27,355 | ) |
|
| (43,743 | ) |
Free Cash Flow |
| $ | 78,200 |
|
| $ | 138,644 |
|
(a) The amounts under "Purchase of property and equipment, net", include immaterial proceeds from sale of property and equipment for the three months ended December 31, 2024 and 2023, respectively.
AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)
|
| Three Months Ended December 31, 2024 |
|
|
| ||||||||||||||||||||
| GAAP |
| Amortization of purchased intangible assets and other |
| Equity based compensation expense |
| Changes in certain acquisitions related liabilities measured at fair value |
| Restructuring charges |
| Other |
| Tax |
| Non-GAAP |
| |||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Cost of revenue |
| $ | 682,259 |
| $ | - |
| $ | (13,250 | ) | $ | - |
| $ | - |
| $ | - |
| $ | - |
| $ | 669,009 |
|
Research and development |
|
| 84,333 |
|
|
|
|
| (2,271 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
| 82,062 |
|
Selling, general and administrative |
|
| 122,087 |
|
|
|
|
| (10,999 | ) |
| 12,498 |
|
|
|
|
|
|
|
|
|
|
| 123,586 |
|
Amortization of purchased intangible assets and other |
|
| 15,759 |
|
| (15,759 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| - |
|
Restructuring charges |
|
| 6,783 |
|
|
|
|
|
|
|
|
|
|
| (6,783 | ) |
|
|
|
|
|
|
| - |
|
Total operating expenses |
|
| 911,221 |
|
| (15,759 | ) |
| (26,520 | ) |
| 12,498 |
|
| (6,783 | ) |
| - |
|
| - |
|
| 874,657 |
|
Operating income |
|
| 198,834 |
|
| 15,759 |
|
| 26,520 |
|
| (12,498 | ) |
| 6,783 |
|
| - |
|
| - |
|
| 235,398 |
|
Interest and other expense, net |
|
| (6,409 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
| 6,048 |
|
|
|
|
| (361 | ) |
Income tax expense |
|
| 40,573 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 5,587 |
|
| 46,160 |
|
Net income |
|
| 151,852 |
|
| 15,759 |
|
| 26,520 |
|
| (12,498 | ) |
| 6,783 |
|
| 6,048 |
|
| (5,587 | ) |
| 188,877 |
|
Net income attributable to noncontrolling interests |
|
| 719 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 719 |
|
Net income attributable to Amdocs Limited |
| $ | 151,133 |
| $ | 15,759 |
| $ | 26,520 |
| $ | (12,498 | ) | $ | 6,783 |
| $ | 6,048 |
| $ | (5,587 | ) | $ | 188,158 |
|
| Three Months Ended December 31, 2023 |
| ||||||||||||||||||||
| GAAP |
| Amortization of purchased intangible assets and other |
| Equity based compensation expense |
| Changes in certain acquisitions related liabilities measured at fair value |
| Other |
| Tax |
| Non-GAAP |
| ||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Cost of revenue |
| $ | 812,744 |
| $ | - |
| $ | (13,527 | ) | $ | 1,583 |
| $ | - |
| $ | - |
| $ | 800,800 |
|
Research and development |
|
| 89,207 |
|
|
|
|
| (1,867 | ) |
|
|
|
|
|
|
|
|
|
| 87,340 |
|
Selling, general and administrative |
|
| 142,504 |
|
|
|
|
| (10,686 | ) |
|
|
|
|
|
|
|
|
|
| 131,818 |
|
Amortization of purchased intangible assets and other |
|
| 16,410 |
|
| (16,410 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
| - |
|
Total operating expenses |
|
| 1,060,865 |
|
| (16,410 | ) |
| (26,080 | ) |
| 1,583 |
|
| - |
|
| - |
|
| 1,019,958 |
|
Operating income |
|
| 184,334 |
|
| 16,410 |
|
| 26,080 |
|
| (1,583 | ) |
| - |
|
| - |
|
| 225,241 |
|
Interest and other expense, net |
|
| (9,778 | ) |
|
|
|
|
|
|
|
|
|
| 1,534 |
|
|
|
|
| (8,244 | ) |
Income tax expense |
|
| 25,834 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 7,330 |
|
| 33,164 |
|
Net income |
|
| 148,722 |
|
| 16,410 |
|
| 26,080 |
|
| (1,583 | ) |
| 1,534 |
|
| (7,330 | ) |
| 183,833 |
|
Net income attributable to noncontrolling interests |
|
| 757 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 757 |
|
Net income attributable to Amdocs Limited |
| $ | 147,965 |
| $ | 16,410 |
| $ | 26,080 |
| $ | (1,583 | ) | $ | 1,534 |
| $ | (7,330 | ) | $ | 183,076 |
|
AMDOCS LIMITED
Condensed Consolidated Balance Sheets
(In thousands)
|
| As of |
| |||||
|
| December 31, |
|
| September 30, |
| ||
ASSETS |
|
|
|
|
|
| ||
Current assets: |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ | 213,833 |
|
| $ | 346,085 |
|
Short-term interest-bearing investments |
|
| 135,175 |
|
|
| 168,242 |
|
Accounts receivable, net, including unbilled |
|
| 990,859 |
|
|
| 1,028,357 |
|
Prepaid expenses and other current assets |
|
| 266,861 |
|
|
| 228,498 |
|
Total current assets |
|
| 1,606,728 |
|
|
| 1,771,182 |
|
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
| 734,400 |
|
|
| 755,601 |
|
Lease assets |
|
| 155,485 |
|
|
| 149,254 |
|
Goodwill and other intangible assets, net |
|
| 3,066,911 |
|
|
| 3,005,637 |
|
Other noncurrent assets |
|
| 730,217 |
|
|
| 704,468 |
|
Total assets |
| $ | 6,293,741 |
|
| $ | 6,386,142 |
|
|
|
|
|
|
|
|
| |
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable, accruals and other |
| $ | 1,230,093 |
|
| $ | 1,315,679 |
|
Lease liabilities |
|
| 38,625 |
|
|
| 39,983 |
|
Deferred revenue |
|
| 116,114 |
|
|
| 115,247 |
|
Total current liabilities |
|
| 1,384,832 |
|
|
| 1,470,909 |
|
Lease liabilities |
|
| 108,722 |
|
|
| 103,462 |
|
Long-term debt, net of unamortized debt issuance costs |
|
| 646,444 |
|
|
| 646,291 |
|
Other noncurrent liabilities |
|
| 647,883 |
|
|
| 666,303 |
|
Total Amdocs Limited Shareholders' equity |
|
| 3,464,263 |
|
|
| 3,456,976 |
|
Noncontrolling interests |
|
| 41,597 |
|
|
| 42,201 |
|
Total equity |
|
| 3,505,860 |
|
|
| 3,499,177 |
|
Total liabilities and equity |
| $ | 6,293,741 |
|
| $ | 6,386,142 |
|
AMDOCS LIMITED
Consolidated Statements of Cash Flows
(In thousands)
| Three months ended |
| ||||||
| 2024 |
|
| 2023 |
| |||
Cash Flow from Operating Activities: |
|
|
|
|
|
| ||
Net income |
| $ | 151,852 |
|
| $ | 148,722 |
|
Reconciliation of net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation, amortization and impairment |
|
| 46,415 |
|
|
| 45,861 |
|
Amortization of debt issuance cost |
|
| 151 |
|
|
| 149 |
|
Equity-based compensation expense |
|
| 26,520 |
|
|
| 26,080 |
|
Deferred income taxes |
|
| 1,651 |
|
|
| (6,683 | ) |
Loss from short-term interest-bearing investments |
|
| 662 |
|
|
| 548 |
|
Net changes in operating assets and liabilities, net of amounts acquired: |
|
|
|
|
|
|
|
|
Accounts receivable, net |
|
| 2,417 |
|
|
| (66,657 | ) |
Prepaid expenses and other current assets |
|
| (14,787 | ) |
|
| 4,452 |
|
Other noncurrent assets |
|
| (7,925 | ) |
|
| (10,538 | ) |
Lease assets and liabilities, net |
|
| (2,329 | ) |
|
| (5,340 | ) |
Accounts payable, accrued expenses and accrued personnel |
|
| (50,837 | ) |
|
| 95,787 |
|
Deferred revenue |
|
| 867 |
|
|
| (25,930 | ) |
Income taxes payable, net |
|
| (5,129 | ) |
|
| (18,066 | ) |
Other noncurrent liabilities |
|
| (43,973 | ) |
|
| (5,998 | ) |
Net cash provided by operating activities |
|
| 105,555 |
|
|
| 182,387 |
|
Cash Flow from Investing Activities: |
|
|
|
|
|
|
|
|
Purchase of property and equipment, net (a) |
|
| (27,355 | ) |
|
| (43,743 | ) |
Proceeds from sale of short-term interest-bearing investments |
|
| 33,362 |
|
|
| 8,534 |
|
Net cash paid for business acquisitions |
|
| (57,083 | ) |
|
| (77,329 | ) |
Net Cash from equity investments and other |
|
| 16,347 |
|
|
| 928 |
|
Net cash used in investing activities |
|
| (34,729 | ) |
|
| (111,610 | ) |
Cash Flow from Financing Activities: |
|
|
|
|
|
|
|
|
Repurchase of shares |
|
| (144,483 | ) |
|
| (158,525 | ) |
Proceeds from employee stock option exercises |
|
| 4,408 |
|
|
| 4,428 |
|
Payments of dividends |
|
| (54,081 | ) |
|
| (51,053 | ) |
Distribution to noncontrolling interests |
|
| (1,323 | ) |
|
| (1,322 | ) |
Payment of contingent consideration and deferred payment of business acquisitions |
|
| (7,599 | ) |
|
| (1,500 | ) |
Net cash used in financing activities |
|
| (203,078 | ) |
|
| (207,972 | ) |
Net decrease in cash and cash equivalents |
|
| (132,252 | ) |
|
| (137,195 | ) |
Cash and cash equivalents at beginning of period |
|
| 346,085 |
|
|
| 520,080 |
|
Cash and cash equivalents at end of period |
| $ | 213,833 |
|
| $ | 382,885 |
|
AMDOCS LIMITED
Supplementary Information
(In millions)
| Three months ended |
| ||||||||||||||||||
| December 31, |
|
| September 30, |
|
| June 30, |
|
| March 31, |
|
| December 31, |
| ||||||
| 2024 |
|
| 2024 |
|
| 2024 |
|
| 2024 |
|
| 2023 |
| ||||||
North America |
| $ | 737.4 |
|
| $ | 835.8 |
|
| $ | 828.8 |
|
| $ | 823.2 |
|
| $ | 838.1 |
|
Europe |
|
| 155.2 |
|
|
| 184.1 |
|
|
| 175.9 |
|
|
| 184.8 |
|
|
| 181.4 |
|
Rest of the World |
|
| 217.4 |
|
|
| 244.0 |
|
|
| 245.3 |
|
|
| 237.8 |
|
|
| 225.7 |
|
Total Revenue |
| $ | 1,110.1 |
|
| $ | 1,263.9 |
|
| $ | 1,250.1 |
|
| $ | 1,245.8 |
|
| $ | 1,245.2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Three months ended |
| |||||||||||||||||
|
| December 31, |
|
| September 30, |
|
| June 30, |
|
| March 31, |
|
| December 31, |
| |||||
|
| 2024 |
|
| 2024 |
|
| 2024 |
|
| 2024 |
|
| 2023 |
| |||||
Managed Services Revenue |
| $ | 728.9 |
|
| $ | 721.4 |
|
| $ | 740.8 |
|
| $ | 720.3 |
|
| $ | 722.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| as of |
| |||||||||||||||||
|
| December 31, |
|
| September 30, |
|
| June 30, |
|
| March 31, |
|
| December 31, |
| |||||
|
| 2024 |
|
| 2024 (*) |
|
| 2024 |
|
| 2024 |
|
| 2023 |
| |||||
12-Month Backlog |
| $ | 4,140 |
|
| $ | 4,060 |
|
| $ | 4,250 |
|
| $ | 4,230 |
|
| $ | 4,210 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(*) Reflects the phase out of certain business activities from the fourth fiscal quarter of 2024 onwards.
SOURCE: Amdocs - IR
View the original press release on ACCESS Newswire
FAQ
What was Amdocs (DOX) revenue in Q1 fiscal 2025?
How much is Amdocs (DOX) twelve-month backlog as of Q1 2025?
What is Amdocs (DOX) revenue guidance for fiscal 2025?
How much did Amdocs (DOX) spend on share repurchases in Q1 2025?